Nexalin Sets July 15 Virtual Shareholder Meeting for Director Elections, Equity Plan Vote

TL;DR

**NXL's upcoming shareholder meeting on July 15th is a must-watch for investors, as key votes on directors and the equity plan could signal major shifts in governance and compensation strategy.**

AI Summary

Nexalin Technology, Inc. (NXL) is holding its Annual Meeting of Stockholders on July 15, 2025, at 10:00 a.m. EST, virtually via https://www.cstproxy.com/nexalin/2025. Key agenda items include the election of five directors, approval of an amendment to the Company's 2023 Equity Incentive Plan, and ratification of CBIZ CPAs P.C. as the independent auditors for the fiscal year ending December 31, 2025. The record date for voting eligibility was June 4, 2025. The filing is a Definitive Proxy Statement (DEF 14A), indicating the company is seeking stockholder approval for these critical governance and compensation matters. While specific revenue and net income figures are not detailed in this DEF 14A, the focus on an equity incentive plan amendment suggests potential strategic moves to attract or retain talent, which could impact future financial performance. The company operates in the electromedical and electrotherapeutic apparatus industry, SIC 3845, and is incorporated in Delaware.

Why It Matters

This DEF 14A filing is crucial for investors as it outlines the governance and compensation decisions Nexalin Technology, Inc. will put to a shareholder vote on July 15, 2025. The election of five directors will shape the company's strategic direction and oversight, directly impacting future operational decisions and investor returns. Furthermore, the proposed amendment to the 2023 Equity Incentive Plan could significantly alter executive and employee compensation structures, potentially influencing talent retention and motivation within the competitive electromedical apparatus sector. Ratifying CBIZ CPAs P.C. as auditors ensures continued financial transparency and compliance, which is vital for maintaining investor confidence and market integrity.

Risk Assessment

Risk Level: medium — The risk level is medium because while this is a routine proxy filing, the proposed amendment to the 2023 Equity Incentive Plan could dilute existing shareholder value if not structured carefully. Additionally, the election of directors, while standard, always carries the inherent risk of changes in strategic direction that may not align with all investor expectations.

Analyst Insight

Investors should carefully review the details of the proposed 2023 Equity Incentive Plan amendment to understand its potential dilutive effects and implications for executive compensation. Shareholders should also research the five director nominees to ensure their qualifications and vision align with long-term company growth and shareholder interests before the July 15, 2025 meeting.

Key Numbers

• 5 — Number of directors (Proposed for election at the Annual Meeting)
• 2025 — Fiscal year end (For which CBIZ CPAs P.C. is proposed as independent auditors)
• 1 — Number of equity incentive plans (Proposed for amendment (2023 Equity Incentive Plan))
• 1 — Number of auditor ratifications (Proposed for approval (CBIZ CPAs P.C.))

Key Players & Entities

• Nexalin Technology, Inc. (company) — Registrant filing DEF 14A
• CBIZ CPAs P.C. (company) — Proposed independent auditors for fiscal year ending December 31, 2025
• United States Securities and Exchange Commission (regulator) — Regulatory body for the filing
• July 15, 2025 (date) — Date of the Annual Meeting of Stockholders
• June 4, 2025 (date) — Record date for voting eligibility
• 10:00 a.m. (Eastern Standard Time) (time) — Start time of the Annual Meeting
• 1776 Yorktown, Suite 550, Houston, Texas 77056 (address) — Business address of Nexalin Technology, Inc.
• 2023 Equity Incentive Plan (plan) — Plan proposed for amendment approval
• Delaware (state) — State of incorporation for Nexalin Technology, Inc.
• 001-41507 (number) — SEC File Number for Nexalin Technology, Inc.

FAQ

Industry Context

Nexalin Technology, Inc. operates in the electromedical and electrotherapeutic apparatus industry (SIC 3845). This sector involves the development and manufacturing of devices used for medical diagnosis and treatment. The industry is characterized by rapid technological advancements, stringent regulatory oversight, and a competitive landscape driven by innovation and clinical efficacy.

Regulatory Implications

As a company in the medical device sector, Nexalin Technology is subject to significant regulatory scrutiny from bodies like the FDA. Any amendments to its equity incentive plans could have implications for financial reporting and corporate governance compliance. The ratification of independent auditors ensures adherence to financial reporting standards.

What Investors Should Do

1. Review the proposals for the Annual Meeting.
2. Vote your shares.
3. Attend the virtual Annual Meeting.

Key Dates

• 2025-07-15: Annual Meeting of Stockholders — Stockholders will vote on the election of directors, amendment to the equity incentive plan, and ratification of auditors.
• 2025-06-04: Record Date for Voting Eligibility — Determines which stockholders are eligible to vote at the Annual Meeting.
• 2025-12-31: Fiscal Year End — The period for which the independent auditors are being ratified.

Glossary

DEF 14A

A Definitive Proxy Statement filed with the SEC, providing detailed information to stockholders before a shareholder meeting. (This document outlines the agenda and proposals for Nexalin Technology's Annual Meeting, requiring stockholder approval.)

Record Date

A specific date set by a company to determine which shareholders are eligible to receive notice of and vote at a shareholder meeting. (Establishes the cutoff for determining voting rights for the July 15, 2025 Annual Meeting.)

Equity Incentive Plan

A plan that allows a company to grant stock options, restricted stock, or other equity-based awards to employees and directors. (Nexalin Technology is seeking approval to amend its 2023 Equity Incentive Plan, which could impact future compensation and stock dilution.)

Independent Auditors

A firm hired by a company to audit its financial statements and provide an independent opinion on their fairness and accuracy. (Stockholders are being asked to ratify the appointment of CBIZ CPAs P.C. as the company's auditors for the fiscal year ending December 31, 2025.)

Year-Over-Year Comparison

This filing is a Definitive Proxy Statement (DEF 14A) for the July 15, 2025 Annual Meeting. Specific comparative financial metrics to a prior filing are not detailed within this document. However, the focus on amending the 2023 Equity Incentive Plan suggests a potential shift or enhancement in the company's strategy for talent management and compensation, which could be a new or evolving point of interest compared to previous disclosures.

Filing Details

This Form DEF 14A (Form DEF 14A) was filed with the SEC on June 17, 2025 regarding Nexalin Technology, Inc. (NXL).

View full filing on EDGAR

View Full Filing

View this DEF 14A filing on SEC EDGAR